XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1

REVERSE MERGER

9 Months Ended

Sep. 30, 2018

REVERSE MERGER [Abstract]

REVERSE MERGER

3.  REVERSE MERGER



Unaudited pro forma information



The operating results of Transgenomic have been included in the Company's consolidated financial statements for all periods after June 29, 2017.



The following unaudited pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1, 2017 and combines Transgenomic’s unaudited condensed consolidated statement of operations for the nine months ended September 30, 2017 with Precipio’s unaudited condensed statement of operations for the nine months ended September 30, 2017:






Dollars in thousands, except per share amounts			September 30, 2017
			Nine Months Ended
Net sales		$	1,742
Net loss available to common stockholders			(22,980)
Loss per common share		$	(3.40)



X

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-URI http://asc.fasb.org/topic&trid=2303972

+ Details

Name:	us-gaap_BusinessCombinationDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_BusinessCombinationsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration